SURPASS-CVOT Demonstrated Noninferiority but Not Superiority for MACE
The SURPASS-CVOT trial showed that tirzepatide (dual GIP/GLP-1 receptor agonist) was noninferior to dulaglutide (selective GLP-1 receptor agonist) for major adverse cardiovascular events (MACE), with a hazard ratio of 0.92 (95.3% CI 0.83-1.01; p = 0.086), but narrowly missed demonstrating superiority 1.
Key MACE Findings
The trial compared tirzepatide directly against an active comparator (dulaglutide 1.5 mg) rather than placebo, reflecting current ethical standards in diabetes cardiovascular outcome trials. When the results were analyzed against an imputed placebo, tirzepatide suggested a potential 28% MACE risk reduction 1. However, this imputed analysis requires cautious interpretation as it was not the primary comparison.
Broader Cardiovascular Outcomes
Beyond the traditional 3-point MACE composite, post hoc analysis revealed more encouraging results:
A 6-component cardiorenal composite endpoint (including all-cause mortality, MI, stroke, coronary revascularization, heart failure hospitalization, and kidney outcomes) occurred in 23.7% of tirzepatide-treated patients versus 27.4% with dulaglutide (HR 0.84; 95% CI 0.79-0.90; P < .001) 2
Sensitivity analyses showed consistent benefit across narrower endpoint definitions, with hazard ratios of 0.86 for both 5-component and 4-component composites 2
Clinical Context and Limitations
Despite tirzepatide achieving substantially greater improvements in glycemic control (0.8% greater HbA1c reduction) and weight loss (7% greater weight loss) compared to dulaglutide, the incremental cardiovascular benefit was modest 1. This raises important questions about whether we are approaching a therapeutic ceiling for cardiovascular protection in type 2 diabetes, particularly when comparing two agents from the incretin class.
Important Caveats
- The trial enrolled patients with established cardiovascular disease and high cardiovascular risk, limiting generalizability to lower-risk populations
- The active comparator design means we cannot definitively quantify tirzepatide's benefit versus true placebo from this trial alone
- Gastrointestinal adverse events were more common with tirzepatide (42.5%) than dulaglutide (35.9%) 2
Comparison to Earlier SURPASS-4 Data
The earlier SURPASS-4 trial, which compared tirzepatide to insulin glargine, showed that adjudicated MACE-4 events (cardiovascular death, MI, stroke, hospitalization for unstable angina) were not increased with tirzepatide compared to glargine (HR 0.74; 95% CI 0.51-1.08) 3. This established cardiovascular safety but was not powered to demonstrate superiority.
The SURPASS-CVOT represents the definitive cardiovascular outcomes trial for tirzepatide, demonstrating that while it matches the cardiovascular protection of a proven GLP-1 receptor agonist, it does not meaningfully exceed it for traditional MACE endpoints 1.